Focused on Developing New Antimicrobial Therapies to Treat Resistant Gram-Negative Infections

All product candidates are investigational only, potential treatments, and have not been approved for commercial use


Learn more about Plazomicin, our late-stage clinical candidate for the potential treatment of MDR Enterobacteriaceae infections.